Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.61 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.61 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4639444 | 0.90 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL8568897 | 0.90 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL28517678 | 0.90 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL965839 | 0.90 | AGTR1 (0.67) | AGTR1AGTR2GP6 | |
| SCHEMBL8638896 | 0.88 | AGTR1 (0.58) | AGTR1AGTR2GP6 | |
| SCHEMBL7828008 | 0.87 | AGTR1 (0.64) | AGTR1AGTR2GP6 | |
| SCHEMBL3872329 | 0.87 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL1458517 | 0.86 | AGTR1 (0.56) | AGTR1AGTR2GP6 | |
| SCHEMBL649 | 0.86 | AGTR1 (0.58) | AGTR1AGTR2GP6 | |
| SCHEMBL17943651 | 0.85 | AGTR1 (0.62) | AGTR1AGTR2GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285509-A | Preparation method and medical application of carbostyril bridged quinolone imidazoles and analogues thereof | 西南大学 | 2023-12-26 | — | — | CN | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-112194631-B | Schiff base bridged sulfaimidazole compound and preparation method and application thereof | 哈尔滨工业大学（深圳） | 2022-08-02 | — | — | CN | disclosed |
| CN-112194631-A | Schiff base bridged sulfaimidazole compound and preparation method and application thereof | 哈尔滨工业大学（深圳） | 2021-01-08 | — | — | CN | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | AGTR1 712/4885AGTR2 878/4885GP6 4719/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | AGTR1 712/4885AGTR2 878/4885GP6 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.